Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder
Publication Date: May 16, 2017
Last Updated: March 14, 2022
Recommendations
When behavioral therapies have failed and pharmacologic treatment of OAB/DO is considered, providers should counsel on the associated risk of cognitive impairment, dementia, and Alzheimer disease associated with anticholinergic medications in comparison with the potential benefits related to improvement in quality of life for the individual patient.
6731
To reduce overall anticholinergic burden, the lowest effective dose should be prescribed, and consideration should be given to alternative medications such as beta-3 agonists in patients at the highest risk.
6731
Consideration should be given to changing or decreasing the dosage of other anticholinergic medications that a patient may be taking.
6731
Third-line therapies such as intradetrusor onabotulinum toxin A or neuromodulation should also be considered in patients not desiring to use medications for OAB/DO because of their adverse effects.
6731
Recommendation Grading
Overview
Title
Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder
Authoring Organization
American Urogynecologic Society
Publication Month/Year
May 16, 2017
Last Updated Month/Year
January 17, 2024
Document Type
Consensus
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Female, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D053201 - Urinary Bladder, Overactive
Keywords
dementia, anticholinergic, overactive bladder, cognitive impairment, involuntary detrusor contraction